The current management of MMM is problematic, as there are limited options that have been shown to impact survival and disease course. Allogeneic stem cell transplantation, although potentially curative in some patients, is not an option for many patients because of older age, lack of donors, and comorbidi-ties. Useful palliative options exist for treating symptoms from the disease, but have overall not improved survival for the disease. Active investigations into novel agents for the therapy of MMM with thalidomide analogs such as lenalidomide and others ongoing. Improved understanding of pathogenetic mechanism of disease or disease progression may hopefully yield therapeutic targets of greater specificity and efficacy.
10. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A: Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 120:801-808, 2001.
11. Koch CA, Li CY, Mesa RA, Tefferi A: Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 78:1223-1233, 2003.
12. Tefferi A, Elliot MA: Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood 96:4007, 2000.
13. Dupriez B, Morel P, Demory JL, et al.: Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system [see comments]. Blood 88:1013-1018, 1996.
14. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW: Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 113:763-771, 2001.
15. Cervantes F, Pereira A, Esteve J, et al.: Identification of "short-lived" and "long-lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol 97:635-640, 1997.
16. Barosi G, Viarengo G, Pecci A, et al.: Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 98:3249-3255, 2001.
17. Guardiola P, Anderson JE, Bandini G, et al.: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative study. Blood 93:2831-2838, 1999.
18. Guardiola P, Anderson JE, Gluckman E: Myelofibrosis with myeloid metaplasia. N Engl J Med 343:659, 2000; discussion: 659-660.
19. Deeg HJ, Appelbaum FR: Stem-cell transplantation for myelofibrosis. N Engl J Med 344:775-776, 2001.
20. Jurado M, Deeg H, Gooley T, et al.: Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. Br J Haematol 112:392-396, 2001.
21. Devine SM, Hoffman R, Verma A, et al.: Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 99:2255-2258, 2002.
22. Daly A, Song K, Nevill T, et al.: Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplantation 32:35-40, 2003.
23. Deeg HJ, Gooley TA, Flowers ME, et al.: Allogeneic hematopoietic stem cell transplantation for myelofi-brosis. Blood 102:3912-3918, 2003.
24. Rondelli D, Barosi G, Bacigalupo A, et al.: Non-myeloab-lative allogeneic HSCT in high risk patients with myelofibrosis. Blood 102:695a, 2003.
25. Anderson JE, Tefferi A, Craig F, et al.: Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 98:586-593, 2001.
26. Guardiola P, Esperou H, Cazalshatem D, et al.: Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol 98:1004-1009,
Was this article helpful?